Monday, March 9, 2009

Analyst React to Merck’s Deal for Schering-Plough

Analysts responded favorably, but discussed risks related to Johnson & Johnson and the rights to drugs Remicade and golimumab.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)